NO20004250L - Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet - Google Patents
Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitetInfo
- Publication number
- NO20004250L NO20004250L NO20004250A NO20004250A NO20004250L NO 20004250 L NO20004250 L NO 20004250L NO 20004250 A NO20004250 A NO 20004250A NO 20004250 A NO20004250 A NO 20004250A NO 20004250 L NO20004250 L NO 20004250L
- Authority
- NO
- Norway
- Prior art keywords
- tag
- monoclonal antibodies
- high affinity
- humanized anti
- affinity monoclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5756—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumour-associated glycolinkage [TAG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1998/003679 WO1999043816A1 (en) | 1998-02-25 | 1998-02-25 | High affinity humanized anti-tag-72 monoclonal antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20004250D0 NO20004250D0 (no) | 2000-08-24 |
| NO20004250L true NO20004250L (no) | 2000-10-24 |
Family
ID=22266462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20004250A NO20004250L (no) | 1998-02-25 | 2000-08-24 | Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1056860B1 (de) |
| JP (1) | JP4080692B2 (de) |
| AT (1) | ATE288960T1 (de) |
| AU (1) | AU758358B2 (de) |
| CA (1) | CA2321932A1 (de) |
| DE (1) | DE69829001T2 (de) |
| IL (1) | IL138021A0 (de) |
| NO (1) | NO20004250L (de) |
| WO (1) | WO1999043816A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| EP1127148B1 (de) * | 1998-10-31 | 2012-08-08 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Varianten des humanisierten monoklonalen anti-krebs antikörpers cc49 |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| AU2003248744C1 (en) | 2002-06-28 | 2009-12-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Humanized anti-TAG-72 CC49 for diagnosis and therapy of human tumors |
| US7589181B2 (en) | 2003-08-29 | 2009-09-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use |
| KR100620554B1 (ko) | 2004-06-05 | 2006-09-06 | 한국생명공학연구원 | Tag-72에 대한 인간화 항체 |
| DK1877102T3 (da) | 2005-04-28 | 2014-07-21 | Danisco Us Inc | Tab-molekyler |
| SG162726A1 (en) * | 2005-05-27 | 2010-07-29 | San Raffaele Centro Fond | Gene vector comprising mi-rna |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2935520B2 (ja) * | 1988-10-19 | 1999-08-16 | ザ ダウ ケミカル カンパニー | ガン治療に用いられる新規高親和性改変抗体系統群 |
-
1998
- 1998-02-25 WO PCT/US1998/003679 patent/WO1999043816A1/en not_active Ceased
- 1998-02-25 EP EP98910057A patent/EP1056860B1/de not_active Expired - Lifetime
- 1998-02-25 IL IL13802198A patent/IL138021A0/xx unknown
- 1998-02-25 AT AT98910057T patent/ATE288960T1/de not_active IP Right Cessation
- 1998-02-25 DE DE69829001T patent/DE69829001T2/de not_active Expired - Lifetime
- 1998-02-25 CA CA002321932A patent/CA2321932A1/en not_active Abandoned
- 1998-02-25 AU AU64393/98A patent/AU758358B2/en not_active Ceased
- 1998-02-25 JP JP2000533556A patent/JP4080692B2/ja not_active Expired - Lifetime
-
2000
- 2000-08-24 NO NO20004250A patent/NO20004250L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1056860B1 (de) | 2005-02-09 |
| AU6439398A (en) | 1999-09-15 |
| IL138021A0 (en) | 2001-10-31 |
| DE69829001T2 (de) | 2006-03-23 |
| EP1056860A1 (de) | 2000-12-06 |
| ATE288960T1 (de) | 2005-02-15 |
| CA2321932A1 (en) | 1999-09-02 |
| WO1999043816A1 (en) | 1999-09-02 |
| JP4080692B2 (ja) | 2008-04-23 |
| AU758358B2 (en) | 2003-03-20 |
| NO20004250D0 (no) | 2000-08-24 |
| DE69829001D1 (de) | 2005-03-17 |
| JP2002504371A (ja) | 2002-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113326T1 (el) | Ανθρωπινα αντισωματα τα οποια δεσμευουν ανθρωπινη il-12 και μεθοδοι παραγωγης τους | |
| EA200800094A1 (ru) | Антитела cd19 и их использование | |
| HUP9901562A2 (hu) | Anti-CEA monoklonális antitestek, az ezeket tartalmazó konjugátumok és ezek felhasználása antitest irányított enzimes előgyógyszer terápiában | |
| WO2005080431A3 (en) | Monoclonal antibodies that specifically bind to folate receptor alpha | |
| BR0311792A (pt) | Anticorpo de receptor anti-igf-i | |
| AU2003205077A1 (en) | Imaging agents and methods of imaging naaladase of psma | |
| IN2009KN02404A (de) | ||
| DK1565489T3 (da) | Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet | |
| DE602006013029D1 (de) | Anti-egfr-antikörper | |
| BRPI0613382A8 (pt) | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor | |
| EP2196474A3 (de) | Therapeutische Zielmolekulen in Krebs | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| HUP0202522A2 (hu) | Radioaktív jelölőkészlet és kötési mérőeljárás | |
| WO1998035693A3 (en) | Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease | |
| WO2004058146A3 (en) | Novel compositions and methods in cancer | |
| IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
| BG101024A (bg) | Моноклонално антитяло срещу сd44v6 | |
| SG146644A1 (en) | Kid3 and kid3 antibodies that bind thereto | |
| WO2004060304A3 (en) | Novel compositions and methods in cancer | |
| ATE248189T1 (de) | Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung | |
| WO2003064593A3 (en) | Antigen panels and methods of using the same | |
| NO20004250D0 (no) | Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet | |
| NO20004251L (no) | Humaniserte anti-CEA monoklonale antistoffer med høy affinitet | |
| EA200600995A1 (ru) | Молекулы, ингибирующие ангиогенез, и их применение в лечении и диагностике рака | |
| EA200601405A1 (ru) | Гуманизированное антитело |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |